ARWR
Arrowhead Pharmaceuticals, Inc.
28.95
USD
This page is just a preview of the data found in TrendSpider’s full version
Arrowhead Pharmaceuticals, Inc. stock is up 17.73% since 30 days ago. The next earnings date is Feb 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.83% of the previous 23 November’s closed higher than October. In the last 4 Unusual Options Trades, there were 3 CALLs, 1 PUT.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 19 Oct 14:01 | 19 Jan, 2024 | 30.00 | 311 | ||
| 19 Oct 14:01 | 15 Mar, 2024 | 30.00 | 583 | ||
| 19 Oct 14:02 | 15 Mar, 2024 | 30.00 | 583 | ||
| 31 Oct 14:38 | 19 Jan, 2024 | 35.00 | 124 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the. treatment of liver diseases associated with alpha-1 antitrypsin deficiency. ARO is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A.
